Section: 8. Immunomodulators and antineoplastics  ➤  8.2. Antineoplastics and supportive medicines  ➤  8.2.1. Cytotoxic medicines

### Cyclophosphamide

- **Indication**: Diffuse large B-cell lymphomas  
  - **ICD11 code**: 2B51

- **INN**: Cyclophosphamide

- **Medicine type**: Chemical agent

- **List type**: Complementary

- **Formulations**:
  - Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
  - Oral > Solid: 25 mg tablet; 50 mg tablet

- **EML status history**:
  - First added in 1977 (TRS 615)
  - Changed in 2015 (TRS 994)
  - Changed in 2019 (TRS 1021)
  - Changed in 2021 (TRS 1035)

- **Sex**: All

- **Age**: Also recommended for children

- **Therapeutic alternatives**: The recommendation is for this specific medicine

- **Patent information**: Patents have expired in most jurisdictions  
  - Read more about patents.

- **Tags**: Cancer

- **Wikipedia**: Cyclophosphamide

- **DrugBank**: Cyclophosphamide

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended the addition of new strength formulations of cyclophosphamide powder for injection (1 g and 2 g) to the EML and EMLc.